Comment on "Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: A Wisconsin Oncology Network Study," by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18

Mitchell Smith; Hossein Borghaei

doi:10.1080/07357900500234146

Comment on "Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: A Wisconsin Oncology Network Study," by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18

Fox Chase Cancer Center

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	572
Number of pages	1
Journal	Cancer Investigation
Volume	23
Issue number	6
DOIs	https://doi.org/10.1080/07357900500234146
State	Published - 2005

Keywords

Antineoplastic Agents, Phytogenic/adverse effects
Clinical Trials, Phase II as Topic
Humans
Lymphoma, Non-Hodgkin/drug therapy
Neoplasm Recurrence, Local/drug therapy
Paclitaxel/adverse effects

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/07357900500234146

Fingerprint

Dive into the research topics of 'Comment on "Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: A Wisconsin Oncology Network Study," by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18'. Together they form a unique fingerprint.

Cite this

@article{bf61b885f6d64c0ab2a1b3486dc6e6f9,

title = "Comment on {"}Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: A Wisconsin Oncology Network Study,{"} by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18",

keywords = "Antineoplastic Agents, Phytogenic/adverse effects, Clinical Trials, Phase II as Topic, Humans, Lymphoma, Non-Hodgkin/drug therapy, Neoplasm Recurrence, Local/drug therapy, Paclitaxel/adverse effects",

author = "Mitchell Smith and Hossein Borghaei",

year = "2005",

doi = "10.1080/07357900500234146",

language = "English",

volume = "23",

pages = "572",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "6",

}

TY - JOUR

T1 - Comment on "Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma

T2 - A Wisconsin Oncology Network Study," by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18

AU - Smith, Mitchell

AU - Borghaei, Hossein

PY - 2005

Y1 - 2005

KW - Antineoplastic Agents, Phytogenic/adverse effects

KW - Clinical Trials, Phase II as Topic

KW - Humans

KW - Lymphoma, Non-Hodgkin/drug therapy

KW - Neoplasm Recurrence, Local/drug therapy

KW - Paclitaxel/adverse effects

UR - http://www.scopus.com/inward/record.url?scp=26844493563&partnerID=8YFLogxK

U2 - 10.1080/07357900500234146

DO - 10.1080/07357900500234146

M3 - Letter

C2 - 16203667

AN - SCOPUS:26844493563

SN - 0735-7907

VL - 23

SP - 572

JO - Cancer Investigation

JF - Cancer Investigation

IS - 6

ER -

Comment on "Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: A Wisconsin Oncology Network Study," by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this